Thursday, June 30, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

CoronaVac provides herd immunity in region of the Colombian Amazon

by Medical Finance
in Coronavirus
Study: Effectiveness of the CoronaVac® vaccine in a region of the Colombian Amazon, was herd immunity achieved? Image Credit: Seda Yalova / Shutterstock.com
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

In a recent study published in the journal Tropical Diseases, Travel Medicine and Vaccines, researchers determine the effectiveness of the CoronaVac® vaccine in a Colombian Amazon population. To this end, the researchers observed robust protection against mortality and severe illness due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and that the indigenous population had achieved herd immunity through mass vaccination.

Study: Effectiveness of the CoronaVac® vaccine in a region of the Colombian Amazon, was herd immunity achieved? Image Credit: Seda Yalova / Shutterstock.com

Study: Effectiveness of the CoronaVac® vaccine in a region of the Colombian Amazon, was herd immunity achieved? Image Credit: Seda Yalova / Shutterstock.com

Background

Herd immunity is defined as the resistance to the spread of an infectious disease within a given population. This phenomenon often occurs when a large part of the community becomes immune to that disease through previous infections or vaccinations. One of the critical advantages of reaching herd immunity is that it reduces the likelihood of infections among individuals with less or no immunity.

The coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 infection, continues to cause severe illness and death in many countries worldwide. As of January 23, 2022, over 60% of the world’s population has received at least one dose of a COVID-19 vaccine, which amounts to nearly 9.87 billion doses of COVID-19 vaccines that have been administered worldwide.

The disease burden of COVID-19 is expected to reduce as a result of protection provided from vaccine-induced immunity across populations, thereby bringing the world closer to possibly achieving herd immunity.

Despite these efforts, various developing countries have not been able to vaccinate as much of their populations. In Colombia, where the incidence of further infection spread and increased severity was high due to its proximity to Brazil, the Colombian Amazon was prioritized with the vaccination program. Of the vaccines administered in this country, including those offered by Sinovac, Pfizer-Biotech, AstraZeneca, Johnson & Johnson, and Moderna, 40% of the Colombian Amazon population have received the Sinovac CoronaVac®.

About the study

The present study aimed to evaluate the effectiveness of CoronaVac® in preventing severe COVID-19, hospitalization, and death in individuals residing within the Colombian Amazon who had been completely vaccinated against COVID-19.

COVID-19 severity is generally defined as mild, moderate, or severe disease. Whereas mild disease is associated with nonspecific symptoms such as fever, pain muscle, or general discomfort, moderate disease is often accompanied by clinical or radiological evidence of lower respiratory infection with compatible lung images. Severe COVID-19 typically is associated with a respiratory rate greater than 30/min, oxygen saturation less than 93%, pressure/inspired oxygen fraction (PaFi) values of less than 300, and infiltrates greater than 50%.

The current study was conducted between February 24, 2021, to August 10, 2021. A total of 7,856 participants were included in the current study, all of whom were older than 18 years old and resided in Mitú, the capital of Vaupés, Colombia, a region located in the southeast of Colombia (Amazonas) bordering Brazil.

Within Mitú, 60.4% of the inhabitants are predominantly indigenous. Of these, 99.9% (7,849 people) received two doses of the CoronaVac® vaccine.

The researchers presented the sociodemographic details of all study participants and details regarding those who were infected with SARS-CoV-2 infected post-vaccination and the level of severity of COVID-19 in the vaccinated population.

Study findings

Describing the incidence of SARS-CoV-2 infections after vaccination and the wave of the peak of cases, the researchers found that 5.7% of vaccinated individuals became ill, and only 0.1% of these require hospitalization. One death, which occurred in an individual over the age of 60, attributable to COVID-19, was reported among the vaccinated individuals.

The fatality rate before the vaccination was 2.2%. However, after vaccination, the fatality rate dropped to 0.22% in the immunized population.

Considering disease severity and vaccination effectiveness, the researchers observed 94.3% effectiveness against mild disease and 99.9% against severe infection. Furthermore, in the case of preventing death attributed to SARS-CoV-2 infection among the vaccinated group, 99.9% vaccine effectiveness was reported. The researchers noted that herd immunity might have been achieved through mass vaccination in this indigenous population based on this solid vaccine effectiveness.

Discussion

Moreover, the observations in this study correlate with previous studies in Brazil, though the data differed in the case of the older population. This difference in the protection could be because of the infection due to the SARS-CoV-2 P1 variant in Brazil. Likewise, compared to different study reports, the difference in the results and observed vaccine effectiveness can be explained due to different epidemiological scenarios.

Notably, the researchers also highlighted the longitudinal protection against morbidity and mortality rendered by the CoronaVac® vaccine, despite possible incidences of the Brazilian variant P.1 of SARS-CoV-2. Because genotypic surveillance is lacking in this population, the researchers could not conclusively account for the infections caused by the variant. Possible breakthrough infections from pediatric populations and responses to new variants have not been fully studied in this vaccinated population.

Conclusions

The current study demonstrated that herd immunity had been achieved through mass vaccination in this population, which has resulted in reduced severe infectious cases and mortality rate from COVID-19.

These findings support the need for continuing vaccination campaigns to provide better protection against infection and emphasize that herd immunity is achievable with maximum mass immunization. Encouragingly, data from this indigenous population suggest the morbidity and mortality rate was significantly reduced with CoronaVac®.

Journal reference:

  • Serrano-Coll, H., Miller, H., Guzmán, C. et al. (2022). Effectiveness of the CoronaVac® vaccine in a region of the Colombian Amazon, was herd immunity achieved? Tropical Diseases, Travel Medicine and Vaccines 8(2). doi:10.1186/s40794-021-00159-x.
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Global Collaboration Concept

Discovering a new possible treatment for COVID-19

by Medical Finance
June 30, 2022
0

In this interview, we speak to Dr. Ahmed G. Ibrahim about his latest research that has discovered a new possible...

Study: Croup Associated With SARS-CoV-2: Pediatric Laryngotracheitis During the Omicron Surge. Image Credit: rumruay / Shutterstock

Evidence of croup associated with SARS-CoV-2

by Medical Finance
June 30, 2022
0

Croup,  inflammation of the subglottic upper airway mucosa manifest as respiratory distress airflow obstruction in children. In addition, it is...

Study: Optimized production and fluorescent labelling of SARS-CoV-2 Virus-Like-Particles to study virus assembly and entry. Image Credit: Kateryna Kon/Shutterstock

Minimal system for SARS-CoV-2 based virus-like particle production to study viral assembly and entry

by Medical Finance
June 30, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers proposed an optimal system to generate severe acute respiratory...

Study: Genetically engineered MRI-trackable extracellular vesicles as SARS-CoV-2 mimetics for mapping ACE2 binding in vivo. Image Credit: Volodymyr Dvornyk/Shutterstock

Researchers create method to track SARS-CoV-2 RBD binding in vivo

by Medical Finance
June 30, 2022
0

Coronavirus disease 2019 (COVID-19) first arose in China, before spreading to nearly every country in the world. It has led...

Surveying communities may be a useful tool for predicting COVID-19 case trajectories

Delays for autism diagnosis and treatment grew even longer during the pandemic

by Medical Finance
June 30, 2022
0

Wylie James Prescott, 3, had to wait more than a year after his autism diagnosis to begin behavioral therapy, even...

Study: An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. Image Credit: Kateryna Kon/Shutterstock

ACE2 decoy receptor with robust neutralization against Omicron subvariants shows therapeutic potential

by Medical Finance
June 30, 2022
0

Researchers in the United States have shown the inhalation of an angiotensin-converting enzyme 2 (ACE2) decoy receptor, sACE22.v2.4-IgG1, increases survival...

Next Post
Small cluster of neurons in the brain stem found to coordinate vocalization with breathing

NUS researchers discover a new way to interpret unsolved Mendelian diseases

Horizontal gene transfer between viruses and hosts plays a major role in driving evolution

Online version of algorithm shows how biases in RNA sequences affect gene expression

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Model-based estimates of deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era. Image Credit: cortex-film/ Shutterstock
    Producing more mRNA COVID vaccines could save 1.5M lives in low/middle-income countries
  • 3D illustration. Colorful DNA molecule. Concept image of a structure of the genetic code. ktsdesign 4c035abf42364e14ad194562cfbdb262 620x480
    Tracking the mutating coronavirus variants
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply